Why Celgene Is Looking Less Risky and More Attractive

Yes Celgene NASDAQ CELG is probably the riskiest big biotech on the planet The company depends on one drug Revlimid for 64 of its revenue It relies on three drugs for nearly 88 of its total revenue more than any other major drugmaker Market research

http://articlefeeds.nasdaq.com/~r/nasdaq/categories/~3/WAHkJN_2qhE/why-celgene-is-looking-less-risky-and-more-attractive-cm998564